Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Intra-cellular Thera74, Inc. (ITCI) since 2013 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Intra-cellular Thera74, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1567514.
Total stock buying since 2013: $37,228,078.
Total stock sales since 2013: $221,630,438.
Total stock option exercises since 2013: $38,819,239.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 0 | $0 | 194,413 | $447,104 |
| 2024 | 0 | $0 | 1,090,880 | $78,720,145 | 1,102,290 | $17,403,636 |
| 2023 | 0 | $0 | 628,333 | $33,154,112 | 448,741 | $6,152,215 |
| 2022 | 0 | $0 | 869,163 | $47,246,424 | 608,335 | $4,920,844 |
| 2021 | 0 | $0 | 709,405 | $29,141,374 | 680,947 | $7,036,339 |
| 2020 | 70,500 | $2,054,880 | 540,983 | $14,573,504 | 495,984 | $1,791,815 |
| 2019 | 880,000 | $9,151,370 | 186,620 | $2,343,330 | 228,332 | $320,240 |
| 2018 | 0 | $0 | 138,314 | $2,559,736 | 105,779 | $93,750 |
| 2017 | 786,490 | $12,188,751 | 34,800 | $549,800 | 142,377 | $289,030 |
| 2016 | 297,000 | $4,651,389 | 9,375 | $142,921 | 30,507 | $40,843 |
| 2015 | 250,000 | $6,000,000 | 234,400 | $11,512,388 | 203,750 | $238,423 |
| 2014 | 208,531 | $3,181,688 | 119,542 | $1,686,704 | 162,500 | $81,250 |
| 2013 | 0 | $0 | 0 | $0 | 12,500 | $3,750 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-03 | 0 | $0 | 0 | $0 | 187,404 | $0 |
| 2025-02 | 0 | $0 | 0 | $0 | 7,009 | $447,104 |
| 2024-12 | 0 | $0 | 102,697 | $8,738,551 | 102,697 | $1,307,332 |
| 2024-11 | 0 | $0 | 41,583 | $3,709,455 | 41,583 | $1,237,842 |
| 2024-08 | 0 | $0 | 305,712 | $22,737,946 | 305,712 | $5,394,110 |
| 2024-06 | 0 | $0 | 24,462 | $1,854,993 | 46,268 | $674,400 |
| 2024-04 | 0 | $0 | 0 | $0 | 20,020 | $344,644 |
| 2024-03 | 0 | $0 | 135,646 | $9,017,257 | 165,961 | $658,282 |
| 2024-02 | 0 | $0 | 177,136 | $12,174,959 | 116,405 | $2,406,371 |
| 2024-01 | 0 | $0 | 303,644 | $20,486,984 | 303,644 | $5,380,655 |
| 2023-12 | 0 | $0 | 21,262 | $1,382,030 | 0 | $0 |
| 2023-11 | 0 | $0 | 42,393 | $2,352,811 | 26,754 | $640,490 |
| 2023-09 | 0 | $0 | 100,000 | $5,393,931 | 0 | $0 |
| 2023-08 | 0 | $0 | 55,300 | $3,251,087 | 55,300 | $1,028,027 |
| 2023-07 | 0 | $0 | 1,842 | $119,730 | 0 | $0 |
| 2023-06 | 0 | $0 | 81,854 | $5,258,546 | 81,854 | $3,503,187 |
| 2023-04 | 0 | $0 | 10,000 | $630,000 | 10,000 | $130,500 |
| 2023-03 | 0 | $0 | 150,129 | $6,747,398 | 68,179 | $65,199 |
| 2023-02 | 0 | $0 | 165,553 | $8,018,579 | 206,654 | $784,812 |
| 2022-12 | 0 | $0 | 183,083 | $9,876,065 | 150,000 | $2,320,500 |
| 2022-09 | 0 | $0 | 65,164 | $2,973,759 | 65,164 | $1,008,087 |
| 2022-08 | 0 | $0 | 40,000 | $2,301,450 | 30,000 | $382,500 |
| 2022-05 | 0 | $0 | 10,000 | $550,000 | 0 | $0 |
| 2022-04 | 0 | $0 | 86,348 | $5,558,220 | 86,348 | $1,099,210 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-10 | Durgam Suresh K. (EVP, Chief Medical Officer) | Option Ex | 7,345 | .00 | 0 |
| 2025-03-10 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 7,345 | .00 | 0 |
| 2025-03-10 | Mates Sharon (Chairman and CEO) | Option Ex | 20,566 | .00 | 0 |
| 2025-03-10 | Halstead Michael (President) | Option Ex | 7,345 | .00 | 0 |
| 2025-03-06 | Durgam Suresh K. (EVP, Chief Medical Officer) | Option Ex | 13,133 | .00 | 0 |
| 2025-03-06 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 13,133 | .00 | 0 |
| 2025-03-06 | Mates Sharon (Chairman and CEO) | Option Ex | 40,712 | .00 | 0 |
| 2025-03-06 | Halstead Michael (President) | Option Ex | 13,133 | .00 | 0 |
| 2025-03-01 | Durgam Suresh K. (EVP, Chief Medical Officer) | Option Ex | 8,742 | .00 | 0 |
| 2025-03-01 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 8,742 | .00 | 0 |
| 2025-03-01 | Mates Sharon (Chairman and CEO) | Option Ex | 34,969 | .00 | 0 |
| 2025-03-01 | Halstead Michael (President) | Option Ex | 12,239 | .00 | 0 |
| 2025-02-24 | Marcus Joel S | Option Ex | 7,009 | 63.79 | 447,104 |
| 2024-12-05 | Mates Sharon (Chairman and CEO) | Sale | 51,697 | 84.38 | 4,362,037 |
| 2024-12-05 | Mates Sharon (Chairman and CEO) | Option Ex | 51,697 | 12.73 | 658,102 |
| 2024-12-04 | Mates Sharon (Chairman and CEO) | Sale | 51,000 | 85.81 | 4,376,514 |
| 2024-12-04 | Mates Sharon (Chairman and CEO) | Option Ex | 51,000 | 12.73 | 649,230 |
| 2024-11-13 | Halstead Michael (President) | Sale | 18,714 | 88.55 | 1,657,031 |
| 2024-11-13 | Halstead Michael (President) | Option Ex | 18,714 | 36.89 | 690,359 |
| 2024-11-12 | Halstead Michael (President) | Sale | 22,869 | 89.75 | 2,052,424 |
| 2024-11-12 | Halstead Michael (President) | Option Ex | 22,869 | 23.94 | 547,483 |
| 2024-08-30 | Mates Sharon (Chairman and CEO) | Sale | 34,396 | 73.03 | 2,511,871 |
| 2024-08-30 | Mates Sharon (Chairman and CEO) | Option Ex | 34,396 | 12.73 | 437,861 |
| 2024-08-29 | Mates Sharon (Chairman and CEO) | Sale | 35,604 | 72.84 | 2,593,537 |
| 2024-08-29 | Mates Sharon (Chairman and CEO) | Option Ex | 35,604 | 12.73 | 453,238 |
| 2024-08-28 | Mates Sharon (Chairman and CEO) | Sale | 32,699 | 73.22 | 2,394,253 |
| 2024-08-28 | Mates Sharon (Chairman and CEO) | Option Ex | 32,699 | 17.57 | 574,521 |
| 2024-08-27 | Mates Sharon (Chairman and CEO) | Sale | 40,513 | 73.63 | 2,983,093 |
| 2024-08-27 | Mates Sharon (Chairman and CEO) | Option Ex | 40,513 | 17.57 | 711,813 |
| 2024-08-26 | Mates Sharon (Chairman and CEO) | Sale | 22,713 | 74.59 | 1,694,230 |
| 2024-08-26 | Mates Sharon (Chairman and CEO) | Option Ex | 22,713 | 17.57 | 399,067 |
| 2024-08-23 | Mates Sharon (Chairman and CEO) | Sale | 28,680 | 74.46 | 2,135,426 |
| 2024-08-23 | Mates Sharon (Chairman and CEO) | Option Ex | 28,680 | 17.57 | 503,907 |
| 2024-08-22 | Mates Sharon (Chairman and CEO) | Sale | 39,380 | 75.02 | 2,954,445 |
| 2024-08-22 | Mates Sharon (Chairman and CEO) | Option Ex | 39,380 | 17.57 | 691,906 |
| 2024-08-21 | Mates Sharon (Chairman and CEO) | Sale | 53,013 | 76.70 | 4,066,044 |
| 2024-08-21 | Mates Sharon (Chairman and CEO) | Option Ex | 53,013 | 17.57 | 931,438 |
| 2024-08-16 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 18,714 | 75.08 | 1,405,047 |
| 2024-08-16 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 18,714 | 36.89 | 690,359 |
| 2024-06-24 | Riggs Rory B | Sale | 4,462 | 75.57 | 337,193 |
| 2024-06-24 | Riggs Rory B | Option Ex | 20,000 | 16.86 | 337,200 |
| 2024-06-23 | Salas Eduardo Rene | Option Ex | 1,567 | .00 | 0 |
| 2024-06-23 | Van Nostrand Robert L | Option Ex | 1,567 | .00 | 0 |
| 2024-06-23 | Marcus Joel S | Option Ex | 1,567 | .00 | 0 |
| 2024-06-23 | Riggs Rory B | Option Ex | 1,567 | .00 | 0 |
| 2024-06-18 | Van Nostrand Robert L | Sale | 20,000 | 75.89 | 1,517,800 |
| 2024-06-18 | Van Nostrand Robert L | Option Ex | 20,000 | 16.86 | 337,200 |
| 2024-04-24 | Mates Sharon (Chairman and CEO) | Option Ex | 20,020 | 17.21 | 344,644 |
| 2024-03-20 | Riggs Rory B | Option Ex | 20,000 | 18.56 | 371,200 |
| 2024-03-11 | Durgam Suresh K. (EVP, Chief Medical Officer) | Sale | 3,712 | 65.97 | 244,880 |
| 2024-03-11 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 7,345 | 65.96 | 484,498 |
| 2024-03-11 | Mates Sharon (Chairman, President & CEO) | Sale | 20,565 | 66.21 | 1,361,608 |
| 2024-03-11 | Hineline Lawrence J. (SVP of Finance, CFO) | Sale | 10,121 | 66.55 | 673,512 |
| 2024-03-11 | Halstead Michael (EVP and General Counsel) | Sale | 7,345 | 66.26 | 486,679 |
| 2024-03-10 | Durgam Suresh K. (EVP, Chief Medical Officer) | Option Ex | 7,345 | .00 | 0 |
| 2024-03-10 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 7,345 | .00 | 0 |
| 2024-03-10 | Mates Sharon (Chairman, President & CEO) | Option Ex | 20,565 | .00 | 0 |
| 2024-03-10 | Hineline Lawrence J. (SVP of Finance, CFO) | Option Ex | 10,121 | 28.36 | 287,082 |
| 2024-03-10 | Halstead Michael (EVP and General Counsel) | Option Ex | 7,345 | .00 | 0 |
| 2024-03-07 | Durgam Suresh K. (EVP, Chief Medical Officer) | Sale | 6,450 | 66.60 | 429,569 |
| 2024-03-07 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 13,132 | 66.66 | 875,379 |
| 2024-03-07 | Mates Sharon (Chairman, President & CEO) | Sale | 40,712 | 66.66 | 2,713,658 |
| 2024-03-07 | Hineline Lawrence J. (SVP of Finance, CFO) | Sale | 13,132 | 66.59 | 874,525 |
| 2024-03-07 | Halstead Michael (EVP and General Counsel) | Sale | 13,132 | 66.47 | 872,949 |
| 2024-03-06 | Durgam Suresh K. (EVP, Chief Medical Officer) | Option Ex | 13,132 | .00 | 0 |
| 2024-03-06 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 13,132 | .00 | 0 |
| 2024-03-06 | Mates Sharon (Chairman, President & CEO) | Option Ex | 40,712 | .00 | 0 |
| 2024-03-06 | Hineline Lawrence J. (SVP of Finance, CFO) | Option Ex | 13,132 | .00 | 0 |
| 2024-03-06 | Halstead Michael (EVP and General Counsel) | Option Ex | 13,132 | .00 | 0 |
| 2024-02-27 | Van Nostrand Robert L | Sale | 20,000 | 72.92 | 1,458,500 |
| 2024-02-27 | Van Nostrand Robert L | Option Ex | 20,000 | 18.56 | 371,200 |
| 2024-02-26 | Durgam Suresh K. (EVP, Chief Medical Officer) | Sale | 4,112 | 70.19 | 288,608 |
| 2024-02-26 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 7,907 | 69.87 | 552,446 |
| 2024-02-26 | Mates Sharon (Chairman, President & CEO) | Sale | 22,590 | 69.32 | 1,565,871 |
| 2024-02-26 | Hineline Lawrence J. (SVP of Finance, CFO) | Sale | 13,337 | 69.43 | 925,961 |
| 2024-02-26 | Hineline Lawrence J. (SVP of Finance, CFO) | Option Ex | 5,882 | 36.89 | 216,986 |
| 2024-02-26 | Halstead Michael (EVP and General Counsel) | Sale | 7,907 | 69.40 | 548,769 |
| 2024-02-26 | Marcus Joel S | Sale | 26,328 | 68.83 | 1,812,235 |
| 2024-02-26 | Marcus Joel S | Option Ex | 36,757 | 49.47 | 1,818,185 |
| 2024-02-23 | Durgam Suresh K. (EVP, Chief Medical Officer) | Option Ex | 7,907 | .00 | 0 |
| 2024-02-23 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 7,907 | .00 | 0 |
| 2024-02-23 | Mates Sharon (Chairman, President & CEO) | Option Ex | 22,590 | .00 | 0 |
| 2024-02-23 | Hineline Lawrence J. (SVP of Finance, CFO) | Option Ex | 7,455 | .00 | 0 |
| 2024-02-23 | Halstead Michael (EVP and General Counsel) | Option Ex | 7,907 | .00 | 0 |
| 2024-02-02 | Durgam Suresh K. (EVP, Chief Medical Officer) | Sale | 6,167 | 67.09 | 413,744 |
| 2024-02-02 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 11,860 | 67.08 | 795,568 |
| 2024-02-02 | Mates Sharon (Chairman, President & CEO) | Sale | 33,885 | 67.06 | 2,272,328 |
| 2024-02-02 | Hineline Lawrence J. (SVP of Finance, CFO) | Sale | 11,183 | 66.98 | 749,037 |
| 2024-02-02 | Halstead Michael (EVP and General Counsel) | Sale | 11,860 | 66.77 | 791,892 |
| 2024-01-18 | Mates Sharon (Chairman, President & CEO) | Sale | 67,917 | 65.72 | 4,463,505 |
| 2024-01-18 | Mates Sharon (Chairman, President & CEO) | Option Ex | 67,917 | 16.86 | 1,145,080 |
| 2024-01-17 | Mates Sharon (Chairman, President & CEO) | Sale | 48,084 | 66.33 | 3,189,411 |
| 2024-01-17 | Mates Sharon (Chairman, President & CEO) | Option Ex | 48,084 | 16.86 | 810,696 |
| 2024-01-16 | Mates Sharon (Chairman, President & CEO) | Sale | 75,361 | 67.13 | 5,058,983 |
| 2024-01-16 | Mates Sharon (Chairman, President & CEO) | Option Ex | 75,361 | 16.86 | 1,270,586 |
| 2024-01-11 | Halstead Michael (EVP and General Counsel) | Sale | 50,000 | 67.07 | 3,353,499 |
| 2024-01-11 | Halstead Michael (EVP and General Counsel) | Option Ex | 50,000 | 18.34 | 916,750 |
| 2024-01-02 | Durgam Suresh K. (EVP, Chief Medical Officer) | Sale | 62,282 | 70.99 | 4,421,586 |
| 2024-01-02 | Durgam Suresh K. (EVP, Chief Medical Officer) | Option Ex | 62,282 | 19.87 | 1,237,543 |
| 2023-12-13 | Durgam Suresh K. (EVP, Chief Medical Officer) | Sale | 21,262 | 65.00 | 1,382,030 |
| 2023-11-06 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 42,393 | 55.50 | 2,352,811 |
| 2023-11-06 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 26,754 | 23.94 | 640,490 |
| 2023-09-19 | Mates Sharon (Chairman, President & CEO) | Sale | 44,413 | 54.17 | 2,405,852 |
| 2023-09-18 | Mates Sharon (Chairman, President & CEO) | Sale | 55,587 | 53.76 | 2,988,079 |
| 2023-08-07 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 55,300 | 58.79 | 3,251,087 |
| 2023-08-07 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 55,300 | 18.59 | 1,028,027 |
| 2023-07-17 | Durgam Suresh K. (EVP, Chief Medical Officer) | Sale | 1,842 | 65.00 | 119,730 |
| 2023-06-14 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 81,854 | 64.24 | 5,258,546 |
| 2023-06-14 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 81,854 | 42.80 | 3,503,187 |
| 2023-04-17 | Van Nostrand Robert L (Director) | Sale | 10,000 | 63.00 | 630,000 |
| 2023-04-17 | Van Nostrand Robert L (Director) | Option Ex | 10,000 | 13.05 | 130,500 |
| 2023-03-28 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 15,604 | 54.44 | 849,403 |
| 2023-03-13 | Durgam Suresh K. (EVP, Chief Medical Officer) | Sale | 7,344 | 44.69 | 328,166 |
| 2023-03-13 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 3,758 | 44.58 | 167,512 |
| 2023-03-13 | Mates Sharon (Chairman, President & CEO) | Sale | 20,565 | 44.57 | 916,582 |
| 2023-03-13 | Mates Sharon (Chairman, President & CEO) | Option Ex | 20,000 | 3.26 | 65,199 |
| 2023-03-13 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 5,582 | 44.55 | 248,706 |
| 2023-03-13 | Halstead Michael (EVP and General Counsel) | Sale | 7,344 | 44.57 | 327,322 |
| 2023-03-10 | Durgam Suresh K. (EVP, Chief Medical Officer) | Option Ex | 7,344 | .00 | 0 |
| 2023-03-10 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 8,550 | 43.12 | 368,676 |
| 2023-03-10 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 7,344 | .00 | 0 |
| 2023-03-10 | Mates Sharon (Chairman, President & CEO) | Sale | 41,770 | 42.90 | 1,791,724 |
| 2023-03-10 | Mates Sharon (Chairman, President & CEO) | Option Ex | 20,565 | .00 | 0 |
| 2023-03-10 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 15,663 | 42.84 | 671,081 |
| 2023-03-10 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 5,582 | .00 | 0 |
| 2023-03-10 | Halstead Michael (EVP and General Counsel) | Sale | 16,708 | 42.86 | 716,104 |
| 2023-03-10 | Halstead Michael (EVP and General Counsel) | Option Ex | 7,344 | .00 | 0 |
| 2023-03-01 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 7,241 | 50.01 | 362,122 |
| 2023-02-24 | Durgam Suresh K. (SVP, Chief Medical Officer) | Sale | 7,906 | 47.14 | 372,688 |
| 2023-02-24 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 4,046 | 47.12 | 190,647 |
| 2023-02-24 | Mates Sharon (Chairman, President & CEO) | Sale | 22,590 | 47.03 | 1,062,407 |
| 2023-02-24 | Mates Sharon (Chairman, President & CEO) | Option Ex | 30,000 | 3.26 | 97,800 |
| 2023-02-24 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 7,455 | 47.03 | 350,608 |
| 2023-02-24 | Halstead Michael (EVP and General Counsel) | Sale | 7,906 | 47.03 | 371,819 |
| 2023-02-23 | Durgam Suresh K. (SVP, Chief Medical Officer) | Option Ex | 7,906 | .00 | 0 |
| 2023-02-23 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 7,906 | .00 | 0 |
| 2023-02-23 | Mates Sharon (Chairman, President & CEO) | Option Ex | 22,590 | .00 | 0 |
| 2023-02-23 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 7,455 | .00 | 0 |
| 2023-02-23 | Halstead Michael (EVP and General Counsel) | Option Ex | 7,906 | .00 | 0 |
| 2023-02-21 | Durgam Suresh K. (SVP, Chief Medical Officer) | Sale | 8,354 | 47.99 | 400,950 |
| 2023-02-21 | Neumann Mark (EVP, Chief Commercial Officer) | Sale | 3,898 | 47.62 | 185,622 |
| 2023-02-21 | Mates Sharon (Chairman, President & CEO) | Sale | 27,848 | 48.05 | 1,338,040 |
| 2023-02-21 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 10,443 | 48.05 | 501,733 |
| 2023-02-21 | Halstead Michael (EVP and General Counsel) | Sale | 11,139 | 48.02 | 534,872 |
| 2023-02-18 | Durgam Suresh K. (SVP, Chief Medical Officer) | Option Ex | 8,354 | .00 | 0 |
| 2023-02-18 | Neumann Mark (EVP, Chief Commercial Officer) | Option Ex | 11,139 | .00 | 0 |
| 2023-02-18 | Mates Sharon (Chairman, President & CEO) | Option Ex | 27,848 | .00 | 0 |
| 2023-02-18 | Hineline Lawrence J. (SVP of Finance CFO) | Option Ex | 10,443 | .00 | 0 |
| 2023-02-18 | Halstead Michael (EVP and General Counsel) | Option Ex | 11,139 | .00 | 0 |
| 2023-02-17 | Hineline Lawrence J. (SVP of Finance CFO) | Sale | 53,968 | 50.20 | 2,709,193 |
Insider trading activities including stock purchases, stock sales, and option exercises of ITCI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Intra-cellular Thera74, Inc. (symbol ITCI, CIK number 1567514) see the Securities and Exchange Commission (SEC) website.